Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belinostat and Zidovudine for Adult T-Cell Leukemia-Lymphoma
NCT02737046Phase 2Completed
- Sponsor
- University of Miami
- Start
- Dec 2016
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of belinostat in adult T-cell leukemia-lymphoma (ATLL), sponsored by University of Miami. Primary endpoints: Complete Molecular Response at 12 months and Adverse Events at 13 months. Started Dec 2016; status: completed.
02
Drugs
belinostat
03
Conditions
adult T-cell leukemia-lymphoma (ATLL)
Beyond the preview
Go deeper on NCT02737046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02737046.